Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. LIVMARLI® (maralixibat) oral solution LIVMARLI® (maralixibat) tablets, for oral useInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
LIVMARLI ® is indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). LIVMARLI is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein [see Clinical Studies (14.2)].
- generic_name
- maralixibat chloride
- product_names
- maralixibat chloride
- ndc
- 79378-110, 79378-110-01, 79378-111, 79378-111-01, 79378-210, 79378-210-30, 79378-215, 79378-215-30, 79378-220, 79378-220-30, 79378-230, 79378-230-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en